Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA5A | P35218 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34520 | 0.98 | CA1 (0.64) | CA1CA2CA9CA12CA4 | |
| Bromide SCHEMBL20984485 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Sulfuric Acid SCHEMBL20984550 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Hydrochloric Acid SCHEMBL20984295 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Ammonia Solution, Strong SCHEMBL11352756 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Water SCHEMBL139057 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Water SCHEMBL139058 | 0.95 | CA1 (0.61) | CA1CA2CA9CA12CA4 | |
| Oxalic Acid SCHEMBL20984369 | 0.90 | CA12 (0.55) | CA1CA2CA9CA12CA4 | |
| Phosphoric Acid SCHEMBL20984425 | 0.90 | CA1 (0.55) | CA1CA2CA9CA12CA4 | |
| Nitric Acid SCHEMBL20984254 | 0.88 | CA1 (0.53) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478512-B2 | Charge-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-11-19 | — | — | US | disclosed |
| US-10201621-B2 | Charge-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180177896-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2393420-B1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170290927-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-10-12 | — | — | US | disclosed |
| US-9687567-B2 | Charged-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150209451-A1 | CHARGED-BALANCED IMAGING AGENTS | BETH ISRAEL HOSPITAL (US) | 2015-07-30 | — | — | US | disclosed |
| US-9023611-B2 | Charged-balanced imaging agents | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120028291-A1 | CHARGED-BALANCED IMAGING AGENTS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2393420-A1 | CHARGE-BALANCED IMAGING AGENTS | Beth Israel Deaconess Medical Center, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091243-A1 | CHARGE-BALANCED IMAGING AGENTS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201621-B2 | Charge-balanced imaging agents | PHOSPHO1, ACTB, CYTH3 | CA1 110/4885CA2 77/4885CA9 281/4885 |
| US-10478512-B2 | Charge-balanced imaging agents | PHOSPHO1, ACTB, CYTH3 | CA1 110/4885CA2 77/4885CA9 281/4885 |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | ATP6V1B1, SLC8B1, PHOSPHO1 | CA1 728/4885CA2 305/4885CA9 704/4885 |
| US-20150209451-A1 | CHARGED-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, ARFGAP1 | CA1 56/4885CA2 116/4885CA9 224/4885 |
| US-20120028291-A1 | CHARGED-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, ARFGAP1 | CA1 56/4885CA2 116/4885CA9 224/4885 |
| US-20170290927-A1 | CHARGE-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, CYTH3 | CA1 110/4885CA2 77/4885CA9 281/4885 |
| US-20180177896-A1 | CHARGE-BALANCED IMAGING AGENTS | PHOSPHO1, ACTB, CYTH3 | CA1 110/4885CA2 77/4885CA9 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.